
Sign up to save your podcasts
Or


In this week's episode we’ll learn more about azacitidine-venetoclax combination therapy for first-line treatment of high-risk myelodysplastic syndromes; a new risk-scoring system for post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia, also known as B-ALL; and a novel mechanism for inotuzumab ozogamicin resistance in B-ALL.
Featured Articles:
By American Society of Hematology4.1
4949 ratings
In this week's episode we’ll learn more about azacitidine-venetoclax combination therapy for first-line treatment of high-risk myelodysplastic syndromes; a new risk-scoring system for post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia, also known as B-ALL; and a novel mechanism for inotuzumab ozogamicin resistance in B-ALL.
Featured Articles:

11,155 Listeners

139 Listeners

318 Listeners

499 Listeners

75 Listeners

26 Listeners

1,156 Listeners

2 Listeners

363 Listeners

372 Listeners

1 Listeners

48 Listeners

189 Listeners

30 Listeners

4 Listeners